Lymphoma Clinical Trials

Lymphoma clinical trials provide ways for patients to access some of the newest and most innovative therapies before those therapies are made available at other hospitals and cancer centers. Clinical trials are typically conducted to compare a new treatment option to the existing “best standard” of care, which can help researchers determine if the new therapy has the potential to be more effective (or cause fewer side effects) than other options that are currently being used. The results of these important trials can help researchers improve treatment options, survival rates and quality of life for current and future lymphoma patients.

Moffitt Cancer Center’s clinical trial program is one of the most robust in the region, conducting numerous studies that focus on both Hodgkin and non-Hodgkin lymphoma. Our lymphoma clinical trials give patients opportunities to access:

  • Novel chemotherapy drugs and combinations
  • Highly targeted radiation therapy delivery techniques
  • Innovative antibiotic and vaccination therapies
  • Treatment options for recurrent lymphomas
  • Treatment options for each specific lymphoma subtype

Moffitt’s lymphoma clinical trials are conducted by experienced researchers and oncologists. Each patient’s progress is continually monitored to ensure that he or she is responding optimally to the recommended treatment. Furthermore, participants are carefully screened for each trial based on individualized factors such as cancer type and age; this increases the likelihood that a patient will benefit more from the specific treatment being tested than the other options that are currently available. And, adaptations can be made to a patient’s treatment plan at any time.

Because of our dedication to conducting groundbreaking research and advancing lymphoma treatment, we have been named a Comprehensive Cancer Center by the National Cancer Institute. We are the only cancer center based in Florida to have received this prestigious recognition.

Click Here to View Clinical Trials

For more information about Moffitt Cancer Center’s lymphoma clinical trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form. We can determine if any of our ongoing studies are appropriate for you. No referral is needed to reach out to Moffitt Cancer Center.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 18964

Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19627

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Disease Site: Non-Hodgkin's Lymphoma, Lymphoma

View Trial Details

CLINICAL TRIAL 19715

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19829

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Disease Site: Non-Hodgkin's Lymphoma, Lymphoid Leukemia

View Trial Details

CLINICAL TRIAL 19877

A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19960

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic Car T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Patients with Relapsed/Refractory Large B-Cell and Follicular Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20069

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20078

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Disease Site: Lung, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20131

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

Disease Site: Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other hematologic

View Trial Details

CLINICAL TRIAL 20266

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Disease Site: Hodgkin's Lymphoma, Other hematologic, Unknown Primary Site

View Trial Details

CLINICAL TRIAL 20385

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin(Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Disease Site: Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20578

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Disease Site: Non-Hodgkin's Lymphoma, Lymphoma

View Trial Details

CLINICAL TRIAL 20608

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 90001

A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

Disease Site: Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20126

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)

Disease Site: Non-Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Leukemia, other, Hodgkin's Lymphoma, Lymphoid Leukemia, Acute Leukemia (ALL, AML), Myelodysplastic syndrome (MDS), NHL - Anaplastic large cell lymphoma (ALCL), NHL - Burkitt's lymphoma, NHL - Diffuse large cell lymphoma, NHL - lymphoblastic lymphoma, Other leukemia

View Trial Details

CLINICAL TRIAL 20372

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20397

A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Disease Site: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 50376

Pilot Study of Using MRD as a Predictor of Response after Axicabtagene Ciloleucel in Patients with Indolent Lymphomas

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 18783

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Leukemia, other, Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Acute Leukemia (ALL, AML), Chronic Leukemia (CLL, CML), Other leukemia

View Trial Details